Rahul Banerjee: ARROW2 was here all this time and just got published in Blood Advances
Rahul Banerjee, Assistant Professor at UW Medicine, shared a post by, Robert Z. Orlowski, on X, adding:
“ARROW2 was here all this time and just got published in Blood Advances! KRd with K56-1x vs K27-2x in RRMM MMsm.
– No change in PFS. Non-non-inferior ORR likely artifactual.
– 9% of patients found K27-2x “inconvenient” vs 3% K56-1x
Nice commentary about time toxicity by authors.”
Quoting Robert Z. Orlowski’s post:
“Myeloma Paper of the Day: Once-weekly KRd56 appears similar to twice-weekly KRd27 for patients with relapsed/refractory myeloma, with ORR 82.5% vs. 86.3%, comparable PFS, and similar safety profiles while enhancing convenience.”
A.R.R.O.W.2: Once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma published in PubMed
Autors: Meletios-Athanasios A Dimopoulos, Daniel Coriu, Sosana Delimpasi, Ivan Spicka, Terry E Upchurch , Belle Fang Rakhshandra Talpur, Edward Anthony Faber Jr, Meral Beksac, Xavier Leleu
Source: Rahul Banerjee/X and Robert Z. Orlowski/X
Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.
